Project description DEENESFRITPL New drugs that can reach the brain Treatment of neurological and neurodegenerative diseases such as Alzheimer’s disease requires drugs that can reach the brain. However, the blood-brain barrier poses a significant obstacle to most treatments to date. Funded by the Marie Skłodowska-Curie Actions programme, the NeuroFerro project will focus on the development of compounds that can cross the blood-brain barrier and inhibit ferroptosis in afflicted neurons. Ferroptosis is a type of cell death characterised by iron-dependent lipid peroxidation. In the brain, lipid peroxidation is linked to the pathophysiology of neurodegeneration. The improved pharmacokinetics of the NeuroFerro inhibitors will provide new treatment options to patients suffering from neurological or neurodegenerative disorders. Show the project objective Hide the project objective Objective FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future application in the treatment of neurodegenerative disorders. Ferroptosis is non-apoptotic programmed cell death that has been linked to the pathophysiological processes of many diseases, including dementia, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Neurological disorders are one of the most significant causes of disability-adjusted life-years and death worldwide with very limited treatment available. Although ferroptosis inhibitors developed by Augustyns and Vanden Berghe (supervisors) are currently best in class compounds, they suffer from no or minor BBB permeability. Therefore the main aim of the project will be the design and synthesis of novel ferroptosis inhibitors with improved pharmacokinetic parameters and high blood-brain barrier permeability to target ferroptosis in neurodegenerative disorders. Fields of science medical and health sciencesbasic medicineneurologydementiaalzheimermedical and health sciencesbasic medicinemedicinal chemistrymedical and health sciencesbasic medicinepharmacology and pharmacypharmacokineticsmedical and health sciencesbasic medicineneurologyparkinsonmedical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis Keywords ferroptosis ferroptosis inhibitors neurodegenerative disorders lipid peroxidation cell death Programme(s) HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme Topic(s) HORIZON-MSCA-2021-PF-01-01 - MSCA Postdoctoral Fellowships 2021 Call for proposal HORIZON-MSCA-2021-PF-01 See other projects for this call Funding Scheme MSCA-PF - MSCA-PF Coordinator UNIVERSITEIT ANTWERPEN Net EU contribution € 239 700,00 Address Prinsstraat 13 2000 Antwerpen Belgium See on map Region Vlaams Gewest Prov. Antwerpen Arr. Antwerpen Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window EU contribution No data Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Ryvu Therapeutics S.A. Poland Net EU contribution € 0,00 Address Leona henryka sternbacha 2 30-394 Kraków See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Makroregion południowy Małopolskie Miasto Kraków Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding No data
